Hansa Biopharma licenses IDEFIRIX to SERB Pharmaceuticals in €115 million deal
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
Solutions designed to help clinicians reduce administrative burden, improve diagnostic accuracy, and spend more time with patients
The event is expected to attract more than 100 senior professionals from pharmaceutical companies, CROs, regulatory agencies, and technology organisations
Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials
BMS is moving beyond conversational AI into what it describes as “agentic” systems
NGI will deliver full end-to-end workflows using both EpiFinder cNUC and EpiFinder GenomePro
Dr. Upadhyay brings over 25 years of global leadership experience across life sciences, regulated manufacturing, diagnostics, and research-led environments
The company’s revenue stood at Rs. 287.68 crore, reflecting a 4.7 percent increase over Rs. 274.71 crore reported in FY25
Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance
By leveraging digital screening and remote consultation, the medical community is moving beyond the confines of the clinic
Subscribe To Our Newsletter & Stay Updated